Stockscreener 앱 받기
86.29
2.08%
-1.83
전일 마감가:
$88.12
열려 있는:
$85.81
하루 거래량:
546.14K
Relative Volume:
0.67
시가총액:
$5.89B
수익:
$189.76M
순이익/손실:
$-196.54M
주가수익비율:
-27.76
EPS:
-3.1087
순현금흐름:
$-156.63M
1주 성능:
+5.36%
1개월 성능:
-9.11%
6개월 성능:
-11.25%
1년 성능:
+66.07%
1일 변동 폭
$85.73
$88.64
1주일 범위
$74.50
$90.80
52주 변동 폭
$45.91
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
86.29 | 5.89B | 189.76M | -196.54M | -156.63M | -3.1087 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-19 | 개시 | RBC Capital Mkts | Outperform |
| 2025-11-25 | 개시 | Citigroup | Buy |
| 2025-11-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-07-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments - Yahoo Finance
Rhythm Pharmaceuticals Setmelanotide FDA Approval, Company Details, and XBRL Filing Information - Minichart
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance UK
Rhythm Pharmaceuticals Announces Changes to Board of Directors - Sahm
Rhythm Pharmaceuticals (RYTM) EVP converts RSUs, now holding 66,030 shares - Stock Titan
RHYTHM (RYTM) director receives 6,808 RSUs and 10,257 stock options - Stock Titan
Rhythm Pharmaceuticals (RYTM) director Kimberly Popovits files initial Form 3 - Stock Titan
Rhythm Pharmaceuticals adds Kim Popovits to board of directors By Investing.com - Investing.com Canada
Kim Popovits joins Rhythm (NASDAQ: RYTM) board as Ed Mathers exits - Stock Titan
Rhythm Pharmaceuticals, Inc. Announces Changes in Board of Directors - MarketScreener
Rhythm Pharmaceuticals adds Kim Popovits to board of directors - Investing.com
Rhythm Pharmaceuticals Announces Appointment of Kim Popovits as Director and Departure of Ed Mathers - Quiver Quantitative
Hennion & Walsh Asset Management Inc. Trims Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (RYTM) reports phase 3 EMANATE trial topline results for setmelanotide - MSN
Strength seen in Rhythm Pharmaceuticals (RYTM): Can its 12.6% jump turn into more strength? - MSN
Rhythm posts first FDA approval for acquired hypothalamic obesity - Longevity.Technology
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength? - qz.com
Rhythm Pharma down after late-stage trial setback for lead asset in rare obesity disorders - MSN
Rhythm Pharma higher after FDA label expansion for lead drug - MSN
Rhythm Pharmaceuticals: Imcivree FDA Approval & Market Growth in 2025News and Statistics - indexbox.io
Rhythm Pharma wins EU backing to expand Imcivree label - MSN
Discipline and Rules-Based Execution in RYTM Response - Stock Traders Daily
RYTM PE Ratio & Valuation, Is RYTM Overvalued - Intellectia AI
Rhythm Pharmaceuticals’ Stock Jumps After New Drug Approval - timothysykes.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading 10.9% HigherShould You Buy? - MarketBeat
Rhythm Pharmaceuticals Surges After FDA Approval for Obesity Treatment - StocksToTrade
Jefferies Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $125 - Moomoo
FDA’s Approval Sparks Optimism for Rhythm Pharmaceuticals - StocksToTrade
-7.42% for Rhythm Pharmaceuticals stock as sellers dominate near key support - Traders Union
Rhythm Pharmaceuticals (RYTM) Is Down 13.3% After EMA Backs IMCIVREE Label Expansion for Hypothalamic Obesity - sahmcapital.com
Vanguard disaggregates holdings; reports 0 shares in Rhythm Pharmaceuticals (NASDAQ: RYTM) - Stock Titan
Rhythm pharma down as FDA extends review period for Imcivree label expansion - MSN
Goldman Sachs Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $158 - Moomoo
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $105 - Moomoo
Rhythm Pharmaceuticals Gains EMA Backing for IMCIVREE Expansion - TipRanks
[8-K] RHYTHM PHARMACEUTICALS, INC. Reports Material Event - Stock Titan
Leerink reiterates Rhythm Pharmaceuticals stock rating on CHMP opinion By Investing.com - Investing.com Canada
Rhythm grabs a new obesity approval; how it edged in where Lilly, Novo have fallen flat - msn.com
Short Squeeze: What is the earnings history of Rhythm Pharmaceuticals IncWeekly Trend Summary & Fast Gain Swing Alerts - baoquankhu1.vn
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for - GlobeNewswire
EU panel backs Rhythm drug for obesity and hunger after brain injury - Stock Titan
TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic ObesitySlideshow (NASDAQ:RYTM) 2026-03-24 - Seeking Alpha
TD Cowen reiterates Buy on Rhythm Pharmaceuticals stock at $130 - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
RYTM: HC Wainwright & Co. Maintains 'Buy' Rating, Raises Price T - GuruFocus
H.C. Wainwright raises Rhythm Pharmaceuticals stock price target on FDA approval - Investing.com Canada
Levels Update: What hedge funds are buying Rhythm Pharmaceuticals IncMarket Rally & Accurate Entry/Exit Alerts - baoquankhu1.vn
Rhythm wins US nod for Imcivree in rare hypothalamic obesity - The Pharma Letter
H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $105 - moomoo.com
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) - BioSpace
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rhythm Pharmaceuticals Inc 주식 (RYTM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| German Christopher Paul | Corporate Controller & CAO |
Mar 04 '26 |
Sale |
89.56 |
5,614 |
502,790 |
160 |
0.49%
1.47%
자본화:
|
볼륨(24시간):